Expanding Gamma Delta T Cells From Thousands to Billions While Characterizing Phenotype & Functional Quality for Allogeneic Immunotherapy Development
- Implementing proprietary expansion methods to scale unconventional gamma delta T cells from low starting numbers to over 100 billion cells while maintaining therapeutic phenotype and functional markers
- Establishing quality control processes using flow cytometry to characterize cells before and after expansion, ensuring potential activation and anti-tumor cytotoxicity exceeding 90 percent
- Investigating tumor microenvironment interactions and immune evasion mechanisms to optimize gamma delta T cell product quality and overcome exhaustion for consistent therapeutic efficacy